We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+27.45%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$855M
AUM Growth
-$72.2M
Cap. Flow
+$34.1M
Cap. Flow %
3.99%
Top 10 Hldgs %
52.05%
Holding
72
New
17
Increased
11
Reduced
9
Closed
25

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$34.2M
2
INSM icon
Insmed
INSM
+$32.4M
3
CYTK icon
Cytokinetics
CYTK
+$26M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$25.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$24.7M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$42.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$30.6M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$30M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$23M
5
IMVT icon
Immunovant
IMVT
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRON icon
26
Disc Medicine
IRON
$2.66B
$12.7M 1.48%
200,000
-735,000
-79% -$42.5M
SYRE icon
27
Spyre Therapeutics
SYRE
$8.17B
$11.6M 1.36%
500,000
+300,000
+150% +$8.8M
EWTX icon
28
Edgewise Therapeutics
EWTX
$5.1B
$10.7M 1.25%
400,000
-50,000
-11% -$1.59M
DYN icon
29
Dyne Therapeutics
DYN
$3.37B
$10.6M 1.24%
450,000
+290,000
+181% +$8.58M
PLRX icon
30
Pliant Therapeutics
PLRX
$70M
$9.88M 1.16%
+750,000
New +$10.2M
DRUG
31
Bright Minds Biosciences
DRUG
$604M
$8.82M 1.03%
+245,000
New +$8.62M
YMAB
32
DELISTED
Y-mAbs Therapeutics
YMAB
$7.83M 0.92%
1,000,000
+200,000
+25% +$2.44M
IMVT icon
33
Immunovant
IMVT
$7.78B
$7.43M 0.87%
300,000
-800,000
-73% -$22.7M
GERN icon
34
Geron
GERN
$848M
$7.08M 0.83%
+2,000,000
New +$7.99M
ACRS icon
35
Aclaris Therapeutics
ACRS
$795M
$5.51M 0.64%
+2,222,222
New +$5.53M
TRVI icon
36
Trevi Therapeutics
TRVI
$2.17B
$5.15M 0.6%
1,250,000
-1,500,000
-55% -$4.8M
ATXS
37
DELISTED
Astria Therapeutics
ATXS
$4.47M 0.52%
500,000
– –
UNCY icon
38
Unicycive Therapeutics
UNCY
$133M
$4.03M 0.47%
507,893
– –
JBIO
39
Jade Biosciences
JBIO
$1.09B
$3.71M 0.43%
+40,000
New +$3.45M
RAPP
40
Rapport Therapeutics
RAPP
$2.01B
$3.71M 0.43%
208,910
– –
ATYR
41
aTyr Pharma
ATYR
$36.9M
$3.62M 0.42%
1,000,000
-1,000,000
-50% -$3.03M
ALLK
42
DELISTED
Allakos
ALLK
$3.51M 0.41%
2,900,000
– –
ELVN icon
43
Enliven Therapeutics
ELVN
$3.68B
$3.15M 0.37%
140,000
-355,000
-72% -$9.2M
SEPN
44
Septerna Inc
SEPN
$1.84B
$3.07M 0.36%
+134,202
New +$3.17M
ARTV
45
Artiva Biotherapeutics
ARTV
$413M
$1.46M 0.17%
145,089
– –
CBIO
46
Crescent Biopharma
CBIO
$623M
$1.34M 0.16%
+54,000
New +$1.47M
NUVB.WS
47
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$15.3K ﹤0.01%
+66,666
New +$8.63K
ADVM
48
DELISTED
Adverum Biotechnologies
ADVM
– –
-416,666
Closed -$2.92M
APLS
49
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-1,000,000
Closed -$28.8M
AVTX icon
50
Avalo Therapeutics
AVTX
$895M
– –
-539,079
Closed -$5.12M
1
2
3

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q4 2024 Portfolio in Review

As of Q4 2024, Logos Global Management held 72 positions worth $855M, down 7.8% from $927M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Logos Global Management deployed $34.1M of net new capital in Q4 2024, opening 17 new positions and adding to 11 existing holdings. Its largest new stake was BioNTech: 300,000 shares worth $34.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Disc Medicine, an estimated $42.5M trimmed.

  • Logos Global Management's largest Q4 2024 buy was BioNTech: 300,000 shares worth $34.2M.
  • Logos Global Management added most to Cytokinetics in Q4 2024, an estimated $26M increase.
  • Logos Global Management's biggest Q4 2024 reduction was Disc Medicine, cutting an estimated $42.5M.
  • Logos Global Management fully exited Celldex Therapeutics in Q4 2024, selling an estimated $30.6M.
  • Logos Global Management's ten largest holdings make up 52% of its $855M portfolio in Q4 2024.
  • Logos Global Management opened 17 new positions and closed 25 in Q4 2024.
  • Logos Global Management's portfolio value fell 7.8% quarter-over-quarter to $855M.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.